The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hemophilia Gene Therapy Market Research Report 2024
Synopsis
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
The global Hemophilia Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
Report Scope
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemophilia Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Segment by Type
Hemophilia A
Hemophilia B
Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
The global Hemophilia Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
Report Scope
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemophilia Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Segment by Type
Hemophilia A
Hemophilia B
Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemophilia Gene Therapy Market Perspective (2019-2030)
2.2 Hemophilia Gene Therapy Growth Trends by Region
2.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hemophilia Gene Therapy Historic Market Size by Region (2019-2024)
2.2.3 Hemophilia Gene Therapy Forecasted Market Size by Region (2025-2030)
2.3 Hemophilia Gene Therapy Market Dynamics
2.3.1 Hemophilia Gene Therapy Industry Trends
2.3.2 Hemophilia Gene Therapy Market Drivers
2.3.3 Hemophilia Gene Therapy Market Challenges
2.3.4 Hemophilia Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemophilia Gene Therapy Players by Revenue
3.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2019-2024)
3.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemophilia Gene Therapy Revenue
3.4 Global Hemophilia Gene Therapy Market Concentration Ratio
3.4.1 Global Hemophilia Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemophilia Gene Therapy Revenue in 2023
3.5 Hemophilia Gene Therapy Key Players Head office and Area Served
3.6 Key Players Hemophilia Gene Therapy Product Solution and Service
3.7 Date of Enter into Hemophilia Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemophilia Gene Therapy Breakdown Data by Type
4.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2019-2024)
4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2025-2030)
5 Hemophilia Gene Therapy Breakdown Data by Application
5.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2019-2024)
5.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hemophilia Gene Therapy Market Size (2019-2030)
6.2 North America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hemophilia Gene Therapy Market Size by Country (2019-2024)
6.4 North America Hemophilia Gene Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemophilia Gene Therapy Market Size (2019-2030)
7.2 Europe Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hemophilia Gene Therapy Market Size by Country (2019-2024)
7.4 Europe Hemophilia Gene Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2019-2030)
8.2 Asia-Pacific Hemophilia Gene Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemophilia Gene Therapy Market Size (2019-2030)
9.2 Latin America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hemophilia Gene Therapy Market Size by Country (2019-2024)
9.4 Latin America Hemophilia Gene Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2019-2030)
10.2 Middle East & Africa Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Spark Therapeutics
11.1.1 Spark Therapeutics Company Detail
11.1.2 Spark Therapeutics Business Overview
11.1.3 Spark Therapeutics Hemophilia Gene Therapy Introduction
11.1.4 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.1.5 Spark Therapeutics Recent Development
11.2 Ultragenyx
11.2.1 Ultragenyx Company Detail
11.2.2 Ultragenyx Business Overview
11.2.3 Ultragenyx Hemophilia Gene Therapy Introduction
11.2.4 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.2.5 Ultragenyx Recent Development
11.3 Shire PLC
11.3.1 Shire PLC Company Detail
11.3.2 Shire PLC Business Overview
11.3.3 Shire PLC Hemophilia Gene Therapy Introduction
11.3.4 Shire PLC Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.3.5 Shire PLC Recent Development
11.4 Sangamo Therapeutics
11.4.1 Sangamo Therapeutics Company Detail
11.4.2 Sangamo Therapeutics Business Overview
11.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Introduction
11.4.4 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.4.5 Sangamo Therapeutics Recent Development
11.5 Bioverativ
11.5.1 Bioverativ Company Detail
11.5.2 Bioverativ Business Overview
11.5.3 Bioverativ Hemophilia Gene Therapy Introduction
11.5.4 Bioverativ Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.5.5 Bioverativ Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Detail
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Hemophilia Gene Therapy Introduction
11.6.4 BioMarin Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.6.5 BioMarin Recent Development
11.7 uniQure
11.7.1 uniQure Company Detail
11.7.2 uniQure Business Overview
11.7.3 uniQure Hemophilia Gene Therapy Introduction
11.7.4 uniQure Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.7.5 uniQure Recent Development
11.8 Freeline Therapeutics
11.8.1 Freeline Therapeutics Company Detail
11.8.2 Freeline Therapeutics Business Overview
11.8.3 Freeline Therapeutics Hemophilia Gene Therapy Introduction
11.8.4 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
11.8.5 Freeline Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
